NASDAQ:RGNX REGENXBIO Q1 2026 Earnings Results & Report $8.07 -0.02 (-0.25%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$8.14 +0.07 (+0.92%) As of 10/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. REGENXBIO missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$1.72 versus the -$1.36 consensus estimate, while revenue of $6.39 million fell short of the $25.84 million estimate by $19.45 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 14, 2026TimeBefore Market OpensConference Call9:30 AM ET REGENXBIO EPS ResultsActual EPS-$1.72Consensus EPS -$1.36Beat/MissMissed by -$0.36One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersREGENXBIO Revenue ResultsActual Revenue$6.39 millionExpected Revenue$25.84 millionBeat/MissMissed by -$19.45 millionYoY Revenue GrowthN/AUpcoming EarningsREGENXBIO's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) REGENXBIO Q1 2026 Earnings FAQ Did REGENXBIO beat earnings estimates for Q1 2026? REGENXBIO (NASDAQ:RGNX) reported earnings of -$1.72 per share for Q1 2026, missing the consensus estimate of -$1.36. The report was announced on Thursday, May 14, 2026. What was REGENXBIO's revenue for Q1 2026? REGENXBIO reported revenue of $6.39 million for Q1 2026, against a consensus estimate of $25.84 million. When is REGENXBIO's next earnings date? REGENXBIO's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for REGENXBIO on the company's earnings history page. REGENXBIO Earnings HeadlinesREGENXBIO (NASDAQ:RGNX) Stock Rating Raised to Strong-Buy at MizuhoOctober 6, 2026 | americanbankingnews.comMizuho initiates coverage of REGENXBIO at outperformOctober 6, 2026 | msn.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 10 at 1:00 AM | Weiss Ratings (Ad)REGENXBIO (NASDAQ:RGNX) Stock Jumps 8.1% - What's Next?October 5, 2026 | americanbankingnews.comMizuho Initiates REGENXBIO at Outperform With $22 Price TargetOctober 5, 2026 | finance.yahoo.comRegenxbio’s two lead gene therapies back Mizuho’s nearly 200% upside callOctober 5, 2026 | msn.comSee More REGENXBIO Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like REGENXBIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on REGENXBIO and other key companies, straight to your email. Email Address About REGENXBIOREGENXBIO (NASDAQ:RGNX) is a biotechnology company focused on developing and commercializing gene therapies for serious diseases. The company’s programs are based primarily on its proprietary NAV AAV Technology Platform, which uses adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells. Its research has emphasized conditions affecting the central nervous system, muscles and other tissues. REGENXBIO’s pipeline has included investigational therapies such as RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I and RGX-202 for Duchenne muscular dystrophy. The company also pursues partnerships and licensing arrangements that extend the use of its AAV technology in additional gene therapy programs. Its platform contributed technology to Zolgensma, a gene therapy developed by Novartis for spinal muscular atrophy. Founded in 2009 and headquartered in Rockville, Maryland, REGENXBIO conducts research and clinical development activities intended for patients in the United States and international markets. The company is led by President and Chief Executive Officer Kenneth T. Mills and works with biotechnology and pharmaceutical partners to advance gene therapy candidates toward potential commercialization.View REGENXBIO ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
